An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
Trial Status: active
Researchers are looking for new ways to treat certain types of advanced gastrointestinal
(GI) cancers. The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or
DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC). An ADC attaches
to a protein on cancer cells and delivers treatment to destroy those cells.
The main goal of this study is to learn if the cancer responds to treatment (gets smaller
or goes away).
Inclusion Criteria
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has one of the following cancers:
- Unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)
- Unresectable or metastatic adenocarcinoma of the biliary tract [intra- or
extrahepatic holangiocarcinoma (CCA) or gallbladder cancer (GBC)]
- Unresectable or metastatic colorectal adenocarcinoma
- Unresectable or metastatic gastric adenocarcinoma
- Gastroesophageal junction adenocarcinoma (GEJAC)
- Esophageal adenocarcinoma (EAC)
- Has received prior therapy for the cancer
- Has a life expectancy of at least 3 months
- If human immunodeficiency virus (HIV) infected, must have well controlled HIV on
antiretroviral therapy (ART)
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that
required steroids or has current ILD/pneumonitis, and/or suspected ILD/pneumonitis
- Has clinically severe pulmonary compromise resulting from intercurrent pulmonary
illnesses
- Has uncontrolled or significant cardiovascular disease
- Has a known additional malignancy that is progressing or has required active
treatment within the past 3 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous
meningitis
- Active autoimmune disease that has required systemic treatment in the past 2 years
- Has not adequately recovered from major surgery or has ongoing surgical
complications
- HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric
Castleman's Disease
Additional locations may be listed on ClinicalTrials.gov for NCT06864169.
Locations matching your search criteria
United States
Connecticut
Guilford
Smilow Cancer Hospital Care Center - Guilford
Status: Active
Name Not Available
New Haven
Yale University
Status: Active
Name Not Available
North Haven
Yale-New Haven Hospital North Haven Medical Center
Status: Active
Name Not Available
Trumbull
Smilow Cancer Hospital Care Center-Trumbull
Status: Active
Name Not Available
Ohio
Cleveland
Case Comprehensive Cancer Center
Status: Approved
Name Not Available
Virginia
Charlottesville
University of Virginia Cancer Center
Status: Active
Name Not Available
Wisconsin
Madison
University of Wisconsin Carbone Cancer Center - University Hospital
